US equities
|
NVDA
$234.84
▲+1.72%
MU
$1,075.42
▼-2.00%
TSLA
$372.41
▲+5.17%
SPCX
$156.68
▲+5.81%
SNDK
$1,717.42
▼-3.93%
AMD
$634.52
▲+3.05%
STX
$806.57
▼-14.70%
INTC
$122.11
▲+1.76%
NVDA
$234.84
▲+1.72%
MU
$1,075.42
▼-2.00%
TSLA
$372.41
▲+5.17%
SPCX
$156.68
▲+5.81%
SNDK
$1,717.42
▼-3.93%
AMD
$634.52
▲+3.05%
STX
$806.57
▼-14.70%
INTC
$122.11
▲+1.76%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
0.7299
+0.0099 (+1.38%)
Delayed Quote
Updated: 11:21 AM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
September 23, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
September 17, 2026
VANCOUVER, BC September 17, 2026 - TheNewswire— StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract delivery...
Via
TheNewswire.com
Topics
Intellectual Property
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
September 17, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
September 11, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
September 08, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
September 04, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
September 01, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
August 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
August 11, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
August 06, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
August 03, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
July 30, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
July 28, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
July 20, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
July 17, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
July 16, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
July 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
July 10, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
July 07, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
June 29, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
June 22, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
June 18, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
June 16, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
June 05, 2026
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare
June 03, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Energy
Intellectual Property
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
May 29, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
May 26, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces 1-for-10 Reverse Share Split
May 19, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
May 18, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
